JP2017534263A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534263A5 JP2017534263A5 JP2017515974A JP2017515974A JP2017534263A5 JP 2017534263 A5 JP2017534263 A5 JP 2017534263A5 JP 2017515974 A JP2017515974 A JP 2017515974A JP 2017515974 A JP2017515974 A JP 2017515974A JP 2017534263 A5 JP2017534263 A5 JP 2017534263A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- recombinant adenovirus
- modified
- substitution
- deletion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701161 unidentified adenovirus Species 0.000 claims description 147
- 102000004169 proteins and genes Human genes 0.000 claims description 70
- 108090000623 proteins and genes Proteins 0.000 claims description 70
- 238000006467 substitution reaction Methods 0.000 claims description 52
- 230000037430 deletion Effects 0.000 claims description 51
- 238000012217 deletion Methods 0.000 claims description 51
- 101710199711 Early E1A protein Proteins 0.000 claims description 40
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 26
- 229960002930 sirolimus Drugs 0.000 claims description 22
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 13
- 108700011259 MicroRNAs Proteins 0.000 claims description 12
- 210000004185 liver Anatomy 0.000 claims description 12
- 239000002679 microRNA Substances 0.000 claims description 12
- 101710145505 Fiber protein Proteins 0.000 claims description 10
- 101710094396 Hexon protein Proteins 0.000 claims description 10
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical class CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 4
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical class ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 claims description 4
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 4
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 4
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 4
- 108091007780 MiR-122 Proteins 0.000 claims description 4
- 101710173835 Penton protein Proteins 0.000 claims description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 4
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims description 4
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 108091051828 miR-122 stem-loop Proteins 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 206010061309 Neoplasm progression Diseases 0.000 claims description 3
- 230000005751 tumor progression Effects 0.000 claims description 3
- 108700026758 Adenovirus hexon capsid Proteins 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 2
- 206010062016 Immunosuppression Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 239000005089 Luciferase Substances 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000000234 capsid Anatomy 0.000 claims description 2
- 230000007547 defect Effects 0.000 claims description 2
- 230000003831 deregulation Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 230000001506 immunosuppresive effect Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 208000023958 prostate neoplasm Diseases 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 208000013076 thyroid tumor Diseases 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 230000010304 tumor cell viability Effects 0.000 claims description 2
- 239000013066 combination product Substances 0.000 claims 2
- 229940127555 combination product Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 description 20
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020153724A JP7416423B2 (ja) | 2014-09-24 | 2020-09-14 | 腫瘍崩壊性腫瘍ウイルスおよび使用の方法 |
| JP2023216375A JP2024038030A (ja) | 2014-09-24 | 2023-12-22 | 腫瘍崩壊性腫瘍ウイルスおよび使用の方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462054724P | 2014-09-24 | 2014-09-24 | |
| US62/054,724 | 2014-09-24 | ||
| PCT/US2015/051745 WO2016049201A1 (en) | 2014-09-24 | 2015-09-23 | Oncolytic tumor viruses and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020153724A Division JP7416423B2 (ja) | 2014-09-24 | 2020-09-14 | 腫瘍崩壊性腫瘍ウイルスおよび使用の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534263A JP2017534263A (ja) | 2017-11-24 |
| JP2017534263A5 true JP2017534263A5 (enExample) | 2018-09-27 |
| JP6764859B2 JP6764859B2 (ja) | 2020-10-07 |
Family
ID=55581955
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515974A Active JP6764859B2 (ja) | 2014-09-24 | 2015-09-23 | 腫瘍崩壊性腫瘍ウイルスおよび使用の方法 |
| JP2020153724A Active JP7416423B2 (ja) | 2014-09-24 | 2020-09-14 | 腫瘍崩壊性腫瘍ウイルスおよび使用の方法 |
| JP2023216375A Pending JP2024038030A (ja) | 2014-09-24 | 2023-12-22 | 腫瘍崩壊性腫瘍ウイルスおよび使用の方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020153724A Active JP7416423B2 (ja) | 2014-09-24 | 2020-09-14 | 腫瘍崩壊性腫瘍ウイルスおよび使用の方法 |
| JP2023216375A Pending JP2024038030A (ja) | 2014-09-24 | 2023-12-22 | 腫瘍崩壊性腫瘍ウイルスおよび使用の方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20170202893A1 (enExample) |
| EP (2) | EP4043021A3 (enExample) |
| JP (3) | JP6764859B2 (enExample) |
| KR (3) | KR20250081944A (enExample) |
| CN (1) | CN108064275A (enExample) |
| AU (3) | AU2015320665B2 (enExample) |
| CA (1) | CA2961748A1 (enExample) |
| DK (1) | DK3198009T3 (enExample) |
| ES (1) | ES2899913T3 (enExample) |
| PL (1) | PL3198009T3 (enExample) |
| WO (1) | WO2016049201A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| DK3198009T3 (da) * | 2014-09-24 | 2021-11-22 | Salk Inst For Biological Studi | Onkolytiske tumorvira og anvendelsesfremgangsmåder |
| ES2837400T3 (es) * | 2015-10-05 | 2021-06-30 | Salk Inst For Biological Studi | Adenovirus sintético con tropismo para los tejidos dañados para su uso en la promoción de la reparación de heridas y regeneración tisular |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| CA3045892A1 (en) * | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| WO2018125970A1 (en) * | 2016-12-30 | 2018-07-05 | Salk Institute For Biological Studies | Synthetic adenoviruses targeting bone tissue and uses thereof |
| SG11201906973TA (en) * | 2017-01-30 | 2019-08-27 | Epicentrx Inc | Multiple transgene recombinant adenovirus |
| EA201990822A1 (ru) | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
| EP3773649A4 (en) | 2018-03-28 | 2022-02-23 | EpicentRx, Inc. | PERSONALIZED CANCER VACCINE |
| BR112020019942A2 (pt) * | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| CN111363726A (zh) * | 2018-12-26 | 2020-07-03 | 上海元宋生物技术有限公司 | 表达干扰素的溶瘤病毒及其应用 |
| WO2020172509A1 (en) * | 2019-02-21 | 2020-08-27 | Unleash Immuno Oncolytics, Inc. | Oncolytic adenoviral vector and methods of use |
| US20220354911A1 (en) * | 2019-09-05 | 2022-11-10 | Klinikum Rechts Der Isar Der Technischen Universität München | Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent |
| EP3812465A1 (en) * | 2019-10-21 | 2021-04-28 | Universität Ulm | Adenovirus comprising a modified adenovirus hexon protein |
| JP2023513794A (ja) * | 2020-02-14 | 2023-04-03 | ソーク インスティテュート フォー バイオロジカル スタディーズ | Ｕｌｋ１／２の阻害剤およびその使用方法 |
| AU2021306714A1 (en) * | 2020-07-06 | 2023-02-02 | Salk Institute For Biological Studies | Oncolytic adenovirus with replication selectivity based on status of p53 transcriptional activity |
| WO2022236080A2 (en) * | 2021-05-06 | 2022-11-10 | Asimov Inc. | Compositions and methods for adeno-associated viral production |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030138405A1 (en) * | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| ATE546531T1 (de) * | 2003-12-31 | 2012-03-15 | Kalobios Inc | Transaktivierungssystem für säugerzellen |
| US7473418B2 (en) * | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
| EP2606127B1 (en) * | 2010-08-16 | 2019-03-20 | Salk Institute For Biological Studies | Adenoviral assembly method |
| CA2867129C (en) * | 2012-03-13 | 2023-11-21 | Salk Institute For Biological Studies | Selective cell targeting using adenovirus and chemical dimers |
| CA2903582C (en) * | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| WO2014170389A1 (en) * | 2013-04-18 | 2014-10-23 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| DK3198009T3 (da) | 2014-09-24 | 2021-11-22 | Salk Inst For Biological Studi | Onkolytiske tumorvira og anvendelsesfremgangsmåder |
-
2015
- 2015-09-23 DK DK15843893.7T patent/DK3198009T3/da active
- 2015-09-23 WO PCT/US2015/051745 patent/WO2016049201A1/en not_active Ceased
- 2015-09-23 EP EP21193392.4A patent/EP4043021A3/en active Pending
- 2015-09-23 PL PL15843893T patent/PL3198009T3/pl unknown
- 2015-09-23 AU AU2015320665A patent/AU2015320665B2/en active Active
- 2015-09-23 KR KR1020257017356A patent/KR20250081944A/ko active Pending
- 2015-09-23 CA CA2961748A patent/CA2961748A1/en active Pending
- 2015-09-23 KR KR1020177011121A patent/KR102608590B1/ko active Active
- 2015-09-23 KR KR1020237040919A patent/KR102814615B1/ko active Active
- 2015-09-23 EP EP15843893.7A patent/EP3198009B1/en active Active
- 2015-09-23 ES ES15843893T patent/ES2899913T3/es active Active
- 2015-09-23 JP JP2017515974A patent/JP6764859B2/ja active Active
- 2015-09-23 CN CN201580063723.9A patent/CN108064275A/zh active Pending
-
2017
- 2017-03-24 US US15/468,565 patent/US20170202893A1/en active Pending
-
2020
- 2020-09-14 JP JP2020153724A patent/JP7416423B2/ja active Active
-
2022
- 2022-05-24 AU AU2022203504A patent/AU2022203504B2/en active Active
-
2023
- 2023-12-22 JP JP2023216375A patent/JP2024038030A/ja active Pending
-
2025
- 2025-05-13 AU AU2025203440A patent/AU2025203440A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017534263A5 (enExample) | ||
| Yamamoto et al. | Recent advances in genetic modification of adenovirus vectors for cancer treatment | |
| Niemann et al. | Oncolytic viruses: adenoviruses | |
| Kanerva et al. | Modified adenoviruses for cancer gene therapy | |
| Kanerva et al. | Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses | |
| US10016470B2 (en) | Oncolytic adenoviruses for cancer treatment | |
| Green et al. | Adenoviral vectors: systemic delivery and tumor targeting | |
| Yamamoto et al. | Current issues and future directions of oncolytic adenoviruses | |
| Johnson et al. | Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents | |
| Bauerschmitz et al. | Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents | |
| Yumul et al. | Epithelial junction opener improves oncolytic adenovirus therapy in mouse tumor models | |
| Dong et al. | ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models | |
| EP3725875A1 (en) | Recombinant adenoviruses and stem cells comprising same | |
| Hedley et al. | Targeted and shielded adenovectors for cancer therapy | |
| Bachtarzi et al. | Cancer gene therapy with targeted adenoviruses | |
| Yamamoto et al. | A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic cancer tissues | |
| Sarkioja et al. | Noninvasive imaging for evaluation of the systemic delivery of capsid‐modified adenoviruses in an orthotopic model of advanced lung cancer | |
| He et al. | 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells | |
| Liu et al. | Effects of G 250 promoter controlled conditionally replicative adenovirus expressing K i67‐si RNA on renal cancer cell | |
| Tysome et al. | Lister vaccine strain of vaccinia virus armed with the endostatin–angiostatin fusion gene: an oncolytic virus superior to dl 1520 (ONYX-015) for human head and neck cancer | |
| Lee et al. | Oncolytic potential of E1B 55 kDa‐deleted YKL‐1 recombinant adenovirus: correlation with p53 functional status | |
| Chia et al. | A conditionally replicating adenovirus for nasopharyngeal carcinoma gene therapy | |
| Wu et al. | Adenovirus targeting to prostate-specific membrane antigen through virus-displayed, semirandom peptide library screening | |
| Alemany | Designing adenoviral vectors for tumor-specific targeting | |
| Han et al. | A novel oncolytic adenovirus selectively silences the expression of tumor-associated STAT3 and exhibits potent antitumoral activity |